VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma

The mitoxantrone liposomal enhances the tissue permeability of mitoxantrone by incorporating liposomal groups compared to the conventional mitoxantrone formulation, while also reducing the concentration of free mitoxantrone, thereby minimizing drug side effects-particularly cardiotoxicity. Building upon this, the investigators aim to investigate the efficacy and safety of the liposomal mitoxantrone hydrochloride injection in patients with secondary AML, AML with extramedullary involvement, or myeloid sarcoma, in order to explore alternative therapeutic strategies for these populations.

Trial Details

NCT ID
NCT07028086
Phase
PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • VAM_GROUP
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • The patient fully understands this study, voluntarily participates, and signs the informed consent form (ICF)
  • Age 18-65 years
  • Clinically diagnosed, previously untreated acute myeloid leukemia (non-APL), meeting any one of the following criteria: a. Secondary acute myeloid …
  • Normal cardiac function, with left ventricular ejection fraction (LVEF) ≥50%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →